This enhanced understanding of the metabolic interplay among obesity, the TME, and cancer survival underscores the potential of targeting metabolic modulators such as FABP4 in the management of drug-resistant CRC. The gene discussed is FABP4; the disease is obesity due to melanocortin 4 receptor deficiency.